Navigation Links
Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies

ell's scientific advisory board, has been a long-term collaborator with the company.

The Handbook of Therapeutic Antibodies (ed: Stephen Dubel; published by Wiley VCH March 2007) presents an up-to-date and comprehensive review for the development, production and therapeutic application of antibodies. For more information, visit http://www.wiley.com.

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are no
'"/>




Page: 1 2 3 4

Related medicine technology :

1. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
2. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
3. Researchers Identify Intracellular Pathway of Alfacells Onconase
4. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
5. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
6. Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
9. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
10. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
11. Gentiums Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:12/16/2009)... Dec. 16 MAQUET Cardiovascular LLC, ... announced that it has signed a three-year ... industry,s leading supply contracting company, for MAQUET,s ... The VASOVIEW products assist healthcare providers in ... arteries using only small incisions. This allows ...
(Date:12/16/2009)... VIEW, Calif., Dec. 16 Frost ... Zachary Bujnoch, looks forward to speaking at ... Summit taking place on January 9, 2010 ... on the emerging market of consumer-based digital ... services. ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, ...
(Date:12/16/2009)... Ill., Dec. 16 Naurex Inc., a ... depression and other CNS disorders based on its ... data presented at a major medical meeting showed ... and anxiolytic-like activity with no signs of the ... the NMDA receptor(1). The studies also showed ...
Breaking Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4Frost & Sullivan to Speak at 2010 International Consumer Electronics Digital Health Summit 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6When Viruses 28Including H1N1 29 and Bacteria are as Close as your Fingertips 3B VirWalls New Innovation Can Disarm Killer Keyboards 6324 1When Viruses 28Including H1N1 29 and Bacteria are as Close as your Fingertips 3B VirWalls New Innovation Can Disarm Killer Keyboards 6324 2The Cancer Pain Drug Market Driven by the Continued Dominance of Opioids Will Increase From 242 3 Billion in 2008 to 243 7 Billion in 2018 6320 1The Cancer Pain Drug Market Driven by the Continued Dominance of Opioids Will Increase From 242 3 Billion in 2008 to 243 7 Billion in 2018 6320 2Picis ED PulseCheck Increases Security and Privacy Protection in Nearly 150 Hospitals Through the Use of DigitalPersona Biometrics 10756 1Picis ED PulseCheck Increases Security and Privacy Protection in Nearly 150 Hospitals Through the Use of DigitalPersona Biometrics 10756 2Picis ED PulseCheck Increases Security and Privacy Protection in Nearly 150 Hospitals Through the Use of DigitalPersona Biometrics 10756 3
... 30 The Laboratory Response Network (LRN), the national ... emergencies, will mark its first decade at its national ... by the Association of Public Health Laboratories (APHL), the ... Federal Bureau of Investigation (FBI) to test for agents ...
... Company preparing to initiate phase III trial -SOUTH SAN ... announced top-line results from their phase II study of ... The data was presented on March 27th at the ... of Medical Genetics by Brendan Lee, M.D., Ph.D., Howard ...
Other Medicine Technology:Nation's Laboratory Response Network Marks First Decade of Protecting Public Health 2Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 2Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 3Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 4
(Date:12/16/2009)... Institute announce the first comprehensive analyses of cancer genomes. ... the DNA of cancer cells which are acquired during ... and a lung cancer, reveal for the first time ... cancers. , Lung cancer causes around one million deaths ... The number of mutations found suggest that a typical ...
(Date:12/16/2009)... work on a malaria elimination study in Africa have ... disease using cell phone records. , The scientists analyzed ... residents of Zanzibar travel and where they go. A ... of Tanzania in East Africa, Zanzibar has drastically reduced ... as part of deliberations on whether to launch a ...
(Date:12/16/2009)... from Episencial Offers Planet-Friendly Organics, Solar-Powered Manufacturing and Sustainable Packaging ... ... Los Angeles, CA (PRWEB) December 16, 2009 -- ... affordable choice in all natural skin care for their children ... for young children featuring the beloved artwork of The Very ...
(Date:12/16/2009)... half, but use in humans is still far off , , ... nature, researchers have built and tested synthetic versions of the ... other cases where blood just won,t stop flowing. , "We ... in degradable stitches, which dissolve in the body," said Erin ... Reserve University, and lead author of a report published ...
(Date:12/16/2009)... leader of Digital Pen and Paper technology and the provider ... today announced that it is ranked among the Fastest Growing ... 2009. , ... (PRWEB) December 16, ... for the capture, digitalization and management of handwritten data. Kayentis ...
Breaking Medicine News(10 mins):Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6Health News:Scientists use cell phone records to predict spread of malaria 2Health News:Scientists use cell phone records to predict spread of malaria 3Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 2Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 3Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 4Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 5Health News:Synthetic Platelets Put the Brakes on Blood Loss 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 3Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2
... of Voorhees facility already ahead of scheduleMARLTON, N.J., Feb. ... sell tax exempt bonds from the New Jersey Health ... 2009. The bonds will be used to continue ... "We have our plan for finance in place and ...
... safety initiative to reduce bloodstream infections in intensive care units ... could save an estimated $3 billion dollars and 30,000 lives ... and will begin in the United Kingdom starting in April. ... in Peru and Chile. , "We ran this program in ...
... 25 Nyer Medical Group, Inc. (Nasdaq: ... as chief financial officer. Ms. Zimmerman, a certified ... of Certified Public Accountants, brings more than 30 years ... For the past ten years, Ms. Zimmerman has ...
... Colo., Feb. 25 Mesa Laboratories, Inc. (Nasdaq: ... for manufacturing quality control applications, today announced the appointment ... brings extensive experience to Mesa from his role as ... Group Inc., a registered investment adviser based in New ...
... Provide Information and Resource Safety NetWASHINGTON, Feb. 25 ... debuted a new alliance that will offer veterans, ... for information about healthcare risks experienced by those ... Health Council, made up of veterans and health ...
... Research Council commends the over 180 Members of ... House urging support for long-standing pro-life policies in upcoming ... and overseas abortions, destructive human embryo experimentation, and organizations ... The letter requests that the riders be included in ...
Other Medicine News:Health News:Virtua Health Takes Next Step for Continuing Hospital Construction 2Health News:Johns Hopkins safety team works to eliminate bloodstream infections in the nation and the world 2Health News:Mesa Labs Announces Appointment of New Director 2Health News:VVA Introduces Collaboration Between Veterans and Private Sector to Address Healthcare Needs for Vets 2Health News:FRC Commends Effort to Protect Pro-Life Riders, Prevent Taxpayer Funded Abortions 2
The computer-optimized optical design produces large, brilliant images of high resolution....
Stryker autoclavable pediatric laparoscopes provide equivalent brightness and resolution along with the unparalleled durability found in larger laparoscopes....
The flexible nature of the vinyl allows the user to reach deeper into the chamber and allows for a greater comfort when working inside the glove box over a long period of time compared to any rigid s...
Bactron IV is designed for high volume, yet requires far less bench space than expected for its capacity and performance features....
Medicine Products: